The prevalence of obesity has increased dramatically in the USA and Europe over the past decade.
1,2 Bariatric surgery has proven to be successful in treating morbid obesity with over 220,000 surgeries performed in the USA and Canada in 2008. 3 Several bariatric surgical methods coexist in healthcare, where Roux-en-Y gastric bypass (RYGB) is considered the gold standard. 4 RYGB results in a reduced gastric volume, complete bypass of the pylorus, partial bypass of the duodenum and proximal jejunum, and a delay in bile inflow to the distal jejunum. The more invasive biliopancreatic diversion with duodenal switch (BPD-DS) results in a partial resection of the stomach with the pylorus retained, bypass of jejunum and proximal ileum, and an approximately 250 cm delay of the bile inlet. Jejunoileal bypass (JIB) is considered to be the most invasive procedure, retaining only the stomach (with pylorus) and distal ileum. 5, 6 As a consequence of bariatric surgery, a number of physiological parameters influencing oral drug bioavailability (F oral ) are altered, including: a reduced gastric capacity and emptying time, altered gastrointestinal (GI) pH, reduced absorption area, altered bile flow and small intestinal transit (SIT), altered substrate exposure to drug-metabolizing enzymes, and active efflux transporters. 5, 7, 8 Patients undergoing bariatric surgery continue to receive various thera peutic drugs without dose adjustments for altered bioavailability, which can potentially lead to no therapeutic effect or higher than required systemic exposure. There are a very limited number of studies that have investigated oral drug exposure post-bariatric surgery. 5, 9 The direction and magnitude of impact on F oral following surgery may depend on the characteristics and invasiveness of the surgical procedure, 10, 11 where the extent of the small intestinal bypass may influence the fraction of dose absorbed through the gut wall (f a ). Bypassing regions highly abundant in drug-metabolizing enzymes can affect the fraction of absorbed drug F G . 6 F H , the fraction that escapes hepatic first-pass metabolism, may be assumed to remain unaltered (Eq. 1). 5, 7, 8 (1)
A level of uncertainty remains regarding the SIT postsurgery, where a reduction in motility has been observed, albeit well-powered clinical studies of SIT in man are lacking. 6, 12, 13 The postsurgical physiology is further complicated by the possibility of small intestinal trauma or adaptation, where an enhanced permeability due to impairment of the mucosa or long-term villi elongation has been observed in rat BPD-DS models. 14, 15 Alterations in the levels of gastric hormones (including: peptide YY, ghrelin, and Glucagon-Like Peptide 1) may lead to redistribution of intestinal blood flow to the submucosa, as observed in dog models. Postsurgical hormonal levels have been observed to vary depending on the bariatric surgical procedure. 13, [16] [17] [18] Due to these multifactorial changes, physiologically based pharmacokinetic (PBPK) modeling enables one to predict, in silico, the effects of various bariatric surgeries in a morbidly obese population. 6 The Advanced Dissolution Absorption and Metabolism (ADAM) model describes the variability in F oral through a physiologically based sevensegment model of the small intestine, including: duodenum, jejunum I and II, and ileum I-IV. The model describes drug release from formulation, dissolution, precipitation,
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rESUltS
Changes in oral drug bioavailability after bariatric surgery were demonstrated for cyclosporine and atorvastatin acid following RYGB, BPD-DS, and JIB. 10, 11, 20, 21 Sex-, age-, height-, and weight-matched simulations were carried out based on the corresponding clinical studies using postbariatric surgery models coupled to a full PBPK distribution model into the Simcyp Simulator (Simcyp Limited (a Certara Company), Sheffield, UK). The results from the comparison of observed vs. simulation studies are as follows:
Cyclosporine
Roux-en-Y gastric bypass. Following RYGB, Marterre and coworkers reported a 194% increase in the daily dose per kg body weight in kidney transplant patients (n = 3) of cyclosporin A (CsA) Sandimmune solution. CsA trough blood levels were monitored from 6 months before RYGB up to 12 months postoperatively, using an immunoassay technique (TDx, Abbott Laboratories). The observed reduction in exposure prompted an increase in the oral dose from 1.8 (±0.5) to 3.5 Jejunoileal bypass. In a case study by Chenhsu et al., 21 CsA blood levels at 2 h after administration at steady state (C2), administered as Neoral microemulsion in controls (n = 7) and post-JIB (n = 1), displayed a reduced exposure when comparing the mean C2 concentration over the administered dose range, reporting a reduction in C2 levels of ~59%.
Simulating demographically matched morbidly obese controls (n = 10·7) and post-JIB patients (SIT = 0.4 h; n = 10·1), cyclosporine displayed a reduction in C2 levels from 452 (153-776) to 357 (103-650) ng/ml at a dose level of 4 mg/kg/day and from 2,528 (388-6089) to 1,632 (571-2,811) ng/ml at a dose of 12 mg/kg/day. Simulated levels corresponded well with the linear regression of observed data as compared with the 5-95% prediction interval. The simulated reduction in oral drug exposure in the post-JIB population as compared with the controls was due to a reduction in f a from 0. 
Atorvastatin
Roux-en-Y gastric bypass. In a clinical trial carried out on 12 morbidly obese patients, atorvastatin was administered as an immediate release tablet of 20-80 mg in fasted state where patients were allowed to eat 2 h after administration. Plasma concentration profiles were obtained from 0-8 h after drug administration before and 3-6 weeks after RYGB. The pre to postsurgical trend in oral exposure displayed a high variability where the overall reported trend displayed a median post/ pre surgery AUC ratio of 1.12 (range: 0.34-2.33), albeit being statistically insignificant. 10 Virtual simulations for oral drug exposure of atorvastatin acid pre-to post-RYGB were conducted in 10 randomized trials, each consisting of 12 age-, sex-, and BMI-matched individuals (n = 10 × 12). Assuming a reduction in SIT as function of the small intestinal bypass (SIT = 3.0 h) resulted in an overall increase in AUC with a simulated median post/ presurgical AUC ratio of 1.13, capturing 100% of observed data within the simulated 95% prediction interval of 0.27-3.80 (Figure 3a-j 
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Assuming a reduced small intestinal motility (RYGB SIT = 5.0 h), the more apparent increase in AUC was the result of an extensive increase in f a .
Biliopancreatic diversion with duodenal switch. Atorvastatin immediate release tablet 20-80 mg administered in the fasted state, allowing feeding at 2 h, displayed a significant increase in oral drug exposure following BPD-DS in 10 morbidly obese patients, with an observed mean AUC ratio of 2.0 (±1.0) and observed increase in the C max from 20.0 ng/ml (±24.9) to 28.0 (±22.5), whereas t max increased from 1.2h (±0.8) to 2.3h (±1.0) post-BPD-DS.
11
Predicted plasma concentration-time profiles of atorvastatin acid were consistent with observed data before surgery in a morbidly obese population (Supplementary Data online).
However, simulated plasma concentration-time profiles following BPD-DS (SIT = 1. Sensitivity analysis was performed to assess the impact of potential physiological alterations postsurgery on the plasma exposure of atorvastatin acid, including the impact of: SIT, gastric emptying time, bile concentration in the terminal ileum, small intestinal enterocyte volume (V ent ), GI CYP3A content, and small intestinal permeability (P eff ). The AUC was insensitive to changes in the postsurgical bile concentration and V ent . Following BPD-DS (SIT = 1.2 h), a fivefold increase in P eff led to a post/presurgical AUC ratio of 1.93 (0.60-5.53), whereas C max displayed a post/presurgical ratio of 4.36 (1.23-9.68). A fivefold increase in Q villi resulted in a minor increase in AUC with a simulated post/ pre-BPD-DS AUC ratio of 1.24 (0.22-3.24) and a C max ratio of 1.86 (0. 47-4.19) . A reduction in GI CYP3A by fivefold gave a post/pre-BPD-DS AUC ratio of 1.13 (0.19-3.06) (Figure 5) .
Pre to post-BPD-DS (SIT = 4.2 h) displayed an AUC ratio of 1.71 (0.74-5.79), C max ratio of 1.56 (0.69-3.39), and a t max ratio of 0.87 (0.51-1.31). In the sensitivity analysis, a twofold increase in Q villi resulted in a post/presurgical AUC ratio of 2.07 (0.86-6.96) and a C max ratio of 1.91 (0.84-4.22), whereas t max remained unaltered. A twofold increase in P eff Gastric emptying had the most apparent impact on t max , where a fivefold increase resulted in a post/pre-BPD-DS ratio of 1.78 (1.11-2.58) ( Figure 5 ).
DiSCUSSiOn Cyclosporine
The immunosuppressant cyclosporine (molecular weight: 1202.61 g/mol) displays poor aqueous solubility and a relatively low permeability due to its lipophilic and bulky character making the compound dependent on bile-mediated solubility to facilitate absorption. 23, 24 The drug is mainly metabolized by CYP3A4 in the intestine and liver and is subject to P-glycoprotein efflux. 25, 26 The oral bioavailability displays a high interindividual variability, ranging from 5 to 89% for Sandimmune formulation, whereas Neoral displays improved absorption properties and an oral bioavailability of 21-73%. 27 The simulated underprediction of Sandimmune TDx trough levels before RYGB surgery was expected and is most likely due to the unspecificity of the immunoassay displaying a high cross-reactivity between the parent compound and metabolites resulting in a significantly higher variability in the trough levels as compared with peak concentrations. 20, 22 Normalizing simulated cyclosporine trough levels to pre-RYGB levels produced a reduction in exposure comparable to observed data. Furthermore, a simulated 194% increase in Sandimmune dose levels recovered presurgical trough levels as stated in the publication. 20 In the simulation study of cyclosporine Neoral, microemulsion pre to post-JIB observed data of the control population was well described within the 95% prediction interval of the simulated data, whereas the observed exposure post-JIB was well described within the 95% prediction interval of simulated data assuming a reduction in SIT time equivalent to the bypass (SIT = 0.4 h). An alternative "what-if" scenario simulating a longer transit time (SIT = 0.7 h) over predicted the observed mean blood concentration post-JIB as reported by Chenhsu et al. (Figure 2) . The overprediction could suggest small intestinal motility to remain unaltered following JIB or be a result of a small postsurgical study population (n = 1), displaying a low study power, albeit the simulated magnitude of reduction in C2 levels post-JIB (SIT = 0.4 h) closely matched the estimated reduction in cyclosporine exposure following JIB in another case study where a patient was subject to a surgical reversal of the procedure. The reversed JIB produced an observed 2.78-fold increase in exposure in the case study. 21, 28 The simulated discrepancy in oral drug exposure of Sandimmune and Neoral pre to post-RYGB, where bariatric surgery had the highest effect on the oral bioavailability of Sandimmune, highlights the importance of formulation characteristics and its impact on oral drug bioavailability 
Atorvastatin
The HMG-CoA reductase inhibitor atorvastatin, which is administered in the acid form, displays a high solubility and permeability. The compound is extensively metabolized in the small intestine and liver, namely by CYP3A4 but also via the UGT1A1 and UGT1A3 route. Atorvastatin acid and the lactone metabolite are also subject to interconversion by the UGTs and another minor chemical pathway. Atorvastatin acid is a substrate of P-glycoprotein efflux and OATP1B1-mediated active hepatic uptake. 29 Trends in simulated oral drug exposure of atorvastatin pre to post-RYGB were consistent with observed data, where simulated trends in f a and F G suggested an interplay between reduced absorption area and bypass of regions highly abundant in CYP3A to be of high importance when considering the overall effect on oral bioavailability. Simulated RYGB (SIT = 3.0 h) produced the closest agreement with observed data of atorvastatin exposure following RYGB, again suggesting a reduction in SIT time to be the most likely consequence of surgery. 10 The inability to recover the observed twofold increase in atorvastatin AUC pre to post-BPD-DS at a simulated SIT of 1.2 h may suggest additional postsurgical physiological parameters to be governing the trend in oral drug bioavailability post-BPD-DS. The exploratory sensitivity analysis identified a number of potential parameters leading to a comparable increase in oral drug exposure pre to post-BPD-DS. An increase in SIT following BPD-DS, corresponding to the linear regression relationship between mouth to cecum transit time and plasma levels of peptide YY, resulted in an AUC ratio of 1.71 (0.74-5.79). Furthermore, a simulated twofold increase in P eff and Q villi , or a twofold reduction in the GI content of CYP3A post-BPD-DS (SIT = 4.2 h) recovered the observed AUC of atorvastatin. The reoccurring underprediction of t max following surgery may be explained by an altered postprandial response causing a delayed absorption.
These findings suggest that additional physiological parameters, such as impairment in permeability or redistribution of intestinal blood flow, may play an important role in governing trends in oral drug exposure pre to immediately post-BPD-DS. The results highlight the surgery-specific trends observed post-bariatric surgery due to the intricate interplay between fluid dynamics, absorption area, transporters, metabolism, and GI physiology.
Current limitations in simulating the impact of oral drug bioavailability following bariatric surgery include the lack of clinical and postsurgical physiological data. Nonetheless, the models integrate all available knowledge on changes known to occur in the GI tract following bariatric surgery and can assist with dosage recommendation when there is an absence of clinical observations. 
16,18
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Conclusions
In this work, we demonstrated the potential of a PBPK and simulation to predict oral drug bioavailability post-bariatric surgery by evaluating earlier developed models using observed data for cyclosporine and atorvastatin. Trends in oral drug exposure of atorvastatin and cyclosporine were predicted well within the 95% prediction interval following RYGB using the previously developed model at a SIT time of 3.0 h. The results suggest a reduction in SIT time to be the most likely scenario following RYGB. The observed increase in atorvastatin exposure following BPD-DS could not be captured using the developed BPD-DS model incorporating all known physiological alterations. A mechanistic PBPK modeling approach has the potential to serve as a tool in examining the impact of physiological alterations on oral drug bioavailability in the absence of clinical data. The demonstrated approach may allow a framework for optimization of oral drug therapy post-bariatric surgery.
MEtHODS
Bariatric surgery model. Sex-, age-, height-, and weightmatched simulations were carried out corresponding to identified clinical studies 10, 11, 20, 21 using the ADAM model coupled to a full PBPK distribution model, incorporated into the Simcyp Simulator (Simcyp, Sheffield, UK) (Eqs. 2-4). 8, 30 Detailed specification for the demographics and physiological parameters of the morbidly obese population have been published previously. 7 Similarly, surgical changes to the anatomy and physiology of GI tract following bariatric surgeries, including: RYGB, BPD-DS, and JIB are defined in an earlier publication. 6 Study population-specific surgical alterations are summarized in table 1.
Cyclosporine. The cyclosporine compound file, available in the Simcyp Simulator compound library, was adapted to account for formulation properties corresponding to Sandimmune solution and Sandimmune Neoral microemulsion (Novartis, East Hanover, NJ), using an aqueous solubility of 0.01 mg/ml and particle sizes of 3.73 and 0.03 μm, respectively, further allowing Neoral to supersaturate freely without precipitation assuming a linear dose-concentration relationship. 31 A full PBPK model was used to describe the cyclosporine distribution, where tissue to plasma partition coefficients (Kps) were obtained from in vivo tissue to plasma concentrations at steady state following intravenous infusion in rat. 32 Atorvastatin acid. Physicochemical parameters for atorvastatin acid were taken from the publication by Lennernäs. 29 Metabolic data were obtained from the in vitro study reported by Jacobsen et al.; 33 CYP3A4 was found to be the main enzyme involved in the formation of the two primary metabolites ortho-and para-hydroxyatorvastatin acid with a minor contribution from CYP2C8. Intersystem extrapolation factors, which correct for differences in intrinsic activity per unit CYP enzyme relative to its native environment, were applied to the kinetic data for recombinantly expressed CYP3A4 and CYP2C8, respectively. Acyl glucuronidation of atorvastatin acid to the lactone and UDPGA-dependent metabolism of atorvastatin acid mainly via UGT1A1 to a minor ether glucuronide was also considered. 34, 35 The resultant intrinsic clearance data were scaled to whole-organ values according to Eqs. 5 and 6. 36 The uptake of atorvastatin acid has been demonstrated in an OATP1B1-transfected cell system (HEK293 cells). 37, 38 Although these in vitro data support the involvement of OATP1B1 in the hepatic uptake of atorvastatin acid, it was found that when used in combination with the metabolic data, the clearance was significantly underpredicted. To recover the plasma concentration time profile of atorvastatin acid before BPD-DS, J max,OATP1B1 and Kp muscle were reestimated to 532.4 pmol/min/million cells and 4.0, using weighted leastsquare Nelder-Mead minimization method in the parameter estimation toolbox within the Simcyp Simulator. Sensitivity analysis was carried out with regard to potential GI physiological parameters subject to potential alterations following surgery due to hormonal alterations, including: SIT time, villous blood flow (Q villi ), gastric emptying, small intestinal bile concentration, the enterocyte volume in the remaining small intestine (V ent ), postsurgical abundance of GI CYP3A (GI CYP3A), and small intestinal effective permeability (P eff ).
Analysis. Simulated data were visually inspected against observed data. In addition, the potential mechanism of changes to oral drug absorption was examined through the simulations in terms of assessing the effects on plasma drug concentration-time profile, maximum plasma drug concentration (C max ), time of maximum plasma drug concentration (t max ), f a , and F G . ford Royal Hospital NHS Foundation Trust and David Turner, Simcyp (a Certara company) for discussions leading up to this work and James Kay for his assistance with the manuscript. Associate editor, A.R.-H. was not involved in the review or decision process for this paper. Simcyp's research is funded by a consortium of pharma companies. 
WHAt QUEStiOn tHiS StUDY ADDrESSED?
3 We report on the evaluation of previously developed bariatric surgery PBPK models by comparing observed vs. predicted impact of surgery on oral exposure of cyclosporine and atorvastatin.
WHAt tHiS StUDY ADDS tO OUr KnOWlEDgE
3 Trends in oral exposure of atorvastatin and cyclosporine were well predicted following RYGB. Observed increase in atorvastatin exposure following BPD-DS could not be captured using the current model.
HOW tHiS MigHt CHAngE CliniCAl PHArMACOlOgY AnD tHErAPEUtiCS
3 The potential of a PBPK modeling approach was demonstrated, allowing a framework for optimizing oral drug therapy post-bariatric surgery. Developed models integrated available knowledge on physiological changes. The study highlights areas of further research, where models are not predictive due to the lack of information on systems parameters.
